$KROS (KEROS THERAPEUTICS) — 8-K: Keros board approves $5 million share repurchase program

Keros Therapeutics' Board of Directors approved a $5 million share repurchase program following receipt of a $20 million development milestone payment from Takeda under the elritercept license agreement. The milestone was triggered by dosing the first patient in the ELRiSE MDS clinical trial. Repurchases may occur in the open market or by other lawful means, with timing and amounts dependent on market conditions and other factors. The program may be modified, suspended, or discontinued at any time.

Keros Therapeutics' Board of Directors approved a $5 million share repurchase program following receipt of a $20 million development milestone payment from Takeda under the elritercept license agreeme